Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts

Xenotransplantation

Volumn 6, Issue 1, 1999, Pages 52-65

  Fiane, Arnt E ^a,e   Mollnes, Tom E ^b   Videm, Vibeke ^c   Hovig, Torstein ^a   Høgåsen, Kolbjørn ^a   Mellbye, Ove J ^a   Spruce, Lynn ^d   Moore, William T ^d   Sahu, Arvind ^d   Lambris, John D ^d  

^a UNIVERSITY OF OSLO   (Norway)

^b NORDLAND HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Complement; Ex vivo perfusion; Hyperacute rejection; Xenograft

Indexed keywords

CD11B ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPSTATIN; FIBRIN; INHIBITOR PROTEIN; L SELECTIN; MYELOPEROXIDASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRIN DEPOSITION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY PERFUSION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SWINE; XENOTRANSPLANTATION;

EID: 0033042537     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3089.1999.00007.x     Document Type: Article

References (32)

1. PLATT JL. The immunological barriers to xenotransplantation. Crit Rev Immunol 1996; 16: 331.
2. DALMASSO AP. The complement system in xenotransplantation. Immunopharmacology 1992; 24: 149.
3. BALDWIN WM III, PRUITT SK, BRAUER RB, DAHA MR, SANFILIPPO F. Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation 1995; 59: 797.
4. COZZI E, WHITE DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964.
5. PRUITT SK, KIRK AD, BOLLINGER RR, MARSH HC Jr, COLLINS BH, LEVIN JL, MAULT JR, HEINLE JS, IBRAHIM S, RUDOLPH AR, BALDWIN WM III, SANFILIPPO F. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
6. KROSHUS TJ, ROLLINS SA, DALMASSO AP, ELLIOT EA, MATIS LA, SQUINTO SP, BOLMAN RM III. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60: 1194.
7. FRYER JP, BLONDIN B, STADLER C, IVANCIC D, RATTNER U, KAPLAN B, KAUFMAN D, ABECASSIS M, STUART F, ANDERSON B. Inhibition of human serum mediated lysis of porcine endothelial cells using a novel peptide which blocks Clq binding to xenoantibody. Transplant Proc 1997; 29: 883.
8. SAHU A, KAY BK, LAMBRIS JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 1996; 157: 884.
9. FIANE AE, VIDEM V, FOERSTER A, SCHOLZ T, PEDERSEN TH, KARLSEN H, SVENNEVIG JL, GEIRAN OR, AASEN AO, MOLLNES TE. An ex vivo model to evaluate hyperacute rejection in a discordant pig-to-human combination. Eur Surg Res 1998; 30: 341.
10. LAUER LL, FIELDS CG, FIELDS GB. Sequence dependence of aspartimide formation during 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis. Lett Peptide Sci 1994; 1: 197.
11. EDWARD WB, FIELDS CG, ANDERSON CJ, PAJEAU TS, WELCH MJ, FIELDS GB. Generally applicable, convenient solid-phase synthesis and receptor affinities of octreotide analogs. J Med Chem 1994; 37: 3749.
12. SOLÉ NA, BARANY G Optimization of solid-phase synthesis of [Ala8]-Dynorphin Al-8. J Org Chem 1992; 57: 5399.
13. MOORE WT. Laser desorption mass spectrometry. Methods of Enzymology 1997; 289: 520.
14. MOLLNES TE, HARBOE M. Neoepitope expression during complement activation - a model for detecting antigenic changes in proteins and activation of cascades. Immunologist 1993; 1: 43.
15. MOLLNES TE. Analysis of in vivo complement activation. In: HERZENBERG LA, WEIR DM, HERZENBERG LA, eds. Weir's Handbook of Experimental Immunology. Boston: Blackwell Science Inc., 1997.
16. FURE H, NIELSEN EW, HACK CE, MOLLNES TE. A neoepitope-based enzyme immunoassay for quantification of Cl-inhibitor in complex with Clr and Cls. Scand J Immunol 1997; 46: 553.
17. WOLBINK GJ, BOLLEN J, BAARS JW, TEN BERGE RJ, SWAAK AJ, PAARDEKOOPER J, HACK CE. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993; 163: 67.
18. GARRED P, MOLLNES TE, LEA T Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27: 329.
19. MOLLNES TE, LEA T, FROLAND SS, HARBOE M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22: 197.
20. MOLLNES TE, REDL H, HØGÅSEN K, BENGTSSON A, GARRED P, SPEILBERG L, LEA T, OPPERMANN M, GÖTZE O, SCHLAG G. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993; 91: 295.
21. VIDEM V. Heparin in clinical doses 'primes' granulocytes to subsequent activation as measured by myeloperoxidase release. Scand J Immunol 1996; 43: 385.
22. VAN BEAUMONT W. Evaluation of hemoconcentration from hematocrit measurements. J Appl Physiol 1972; 32: 712.
23. ARMBRUSTER BL, CARLEMALM E, CHIOVETTI R, GARAVITO RM, HOBOT JA, KELLENBERG E, VILLIGER W. Specimen preparation for electron microscopy using low temperature embedding resins. J Microsc 1982; 126: 77.
24. ROBERTSON D, MONAGHAN P, CLARKE C, ATHERTON AJ. An appraisal of low-temperature embedding by progressive lowering of temperature into Lowicryl HM20 for immunocytochemical studies. J Microsc 1992; 168: 85.
25. VIDEM V, FOSSE E, MOLLNES TE, GARRED P, SVENNEVIG JL. Time for new concepts about measurement of complement activation by cardiopulmonary bypass? Ann Thorac Surg 1992; 54: 725.
26. ELLIOTT MJ, FINN AH. Interaction between neutrophils and endothelium. Ann Thorac Surg 1993; 56: 1503.
27. MAMMEN EF, KOETS MH, WASHINGTON BC, WOLK LW, BROWN JM, BURDICK M, SELIK NR, WILSON RF. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985; 11: 281.
28. SAHU A, PANGBURN MK. Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol 1993; 30: 679.
29. MAILLET F, PETITOU M, CHOAY J, KAZATCHKINE MD. Structure-function relationships in the Inhibitory effect of heparin on the complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol Immunol 1988; 25: 917.
30. FAYMONVILLE ME, PINCEMAIL J, DUCHATEAU J, PAULUS JM, ADAM A, LARBUISSON R, LIMET R, LAMY M. Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1991; 102: 309.
31. CAIRO MS, ALLEN J, HIGGINS C, BAEHNER RL, BOXER LA. Synergistic effect of heparin and chemotactic factor on polymorphonuclear leukocyte aggregation and degranulation. Am J Pathol 1983; 113: 67.
32. KESTIN AS, VALERI CR, KHURI SF, LOSCALZO J, ELLIS PA, MACGREGOR H, BIRJINIUK V, OUIMET H, PASCHE B, NELSON MJ, BENOTT SE, RODINO LJ, BARNARD MR, MICHELSON AD. The platelet function defect of cardiopulmonary bypass. Blood 1993; 82: 107.